This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer
by Zacks Equity Research
Revolution Medicines stock tanks after a WSJ report said Merck has withdrawn from buyout talks over price.
MRKPositive Net Change ALKSPositive Net Change ABBVPositive Net Change RVMDPositive Net Change
biotechs
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
by Zacks Equity Research
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
ALKSPositive Net Change SRPTNegative Net Change CSTLNegative Net Change KROSPositive Net Change
biotechs
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?
by Ahan Chakraborty
NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
by Ekta Bagri
Keros Therapeutics advances KER-065 toward DMD trials, trims costs, and extends its cash runway as investors weigh it against Dyne???s deeper pipeline
DYNPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?
by Kanishka Das
Axsome's Auvelity delivered robust 2025 sales growth. A pending FDA decision in 2026 could unlock a broader market and drive sales further.
JAZZNegative Net Change ACADPositive Net Change AXSMPositive Net Change
biotechs
Is KROS' KER-065 the Next Breakthrough in DMD Space?
by Ekta Bagri
KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.
SRPTNegative Net Change PTCTPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results?
by Ahan Chakraborty
Novo Nordisk's Q4 results hinge on Ozempic and Wegovy sales as demand growth slows amid guidance cuts due to intense rivalry and compounded drug headwinds.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?
by Kanishka Das
CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechs
Biotech ETF (XBI) Hits New 52-Week High
by Zacks Equity Research
XBI surges to a 52-week high, nearly doubling from its low, fueled by biotech momentum, AI adoption and easing macro trends.
XBIPositive Net Change
biotechs etfs
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings
by Ahan Chakraborty
LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals